GLP-1 Market
LLY $1208.74 ▲ +3.6% NVO $38.12 ▲ +0.2% PFE $29.21 ▲ +3.0% VKTX $25.47 ▼ -4.4% KLRA $10.74 ▼ -0.3% GPCR $21.88 ▼ -1.9% RHHBY $55.67 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Sonlicromanol

Company
Khondrion BV
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for Sonlicromanol and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06451757

    KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

    Not yet reported Khondrion BV 220 participants Est. completion 2029-09 10 sites Stand-alone
    Cardiovascular disease Other conditions: Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
    View official trial listing →
  • Recruiting NCT NCT07298005

    Sonlicromanol in Post-COVID

    Not yet reported Michele van Vugt 80 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Post COVID Condition
    View official trial listing →
  • Completed NCT NCT04165239

    The KHENERGYZE Study

    Not yet reported Khondrion BV 27 participants Est. completion 2022-05-24 4 sites
    Other conditions: Mitochondrial Diseases, Mitochondrial Myopathies, Mitochondrial Encephalomyopathies, MELAS Syndrome, MIDD
    View official trial listing →
  • Suspended NCT NCT04846036

    The KHENERGYC Study

    Not yet reported Khondrion BV 24 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS, Subacute Necrotizing Encephalomyelopathy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.